The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases especially SYK (Spleen Tyrosine Kinase) LRRK2 (Leucine rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases inflammatory diseases bone diseases metabolic diseases neurological and neurodegenerative diseases cancer cardiovascular diseases allergies asthma alzheimer s disease parkinson s disease skin disorders eye diseases infectious diseases and hormone related diseases.
